ACP3 and prostate neoplasm: We evaluated the antitumor efficacy of SNAs formulated with CpG and PAP115−123 in the murine TRAMP-C2 prostate tumor model; TRAMP-C2 tumor cells express prostate acidic phosphatase (PAP) (39).